Jilin Jian Yisheng Biopharma and the US Army Medical Research Institute of Infectious Diseases reported positive animal results for an Ebola vaccine. The vaccine combines a virus-like particle-based vaccine developed by the USMRIID with Yisheng’s PIKA adjuvant, a Toll-Like Receptor 3 agonist. By itself, the vaccine provided protection for 40% of the animals. With Yisheng’s adjuvant, 100% of the animals survived an Ebola infection. Yisheng, which makes vaccines and pharma products, announced the collaboration with USAMRI in late 2015.
